Pramlintide cut post-meal glucagon by 63% and glucose spikes by 79% in type 1 diabetes, while liraglutide had no effect on either.
79% reductionPramlintide cut the post-meal glucose surge by 79% in type 1 diabetes by suppressing the dysregulated glucagon response
What the researchers found
Pramlintide (an amylin analog peptide) significantly suppressed meal-stimulated glucagon responses in type 1 diabetes patients after 3–4 weeks of treatment. The glucagon area under the curve dropped by 63% (1,988 to 737 pg/mL/min, p<0.001), and the post-meal glucose rise dropped dramatically (11,963 to 2,493 mg/dL/min, p<0.01).
In contrast, liraglutide (a GLP-1 receptor agonist) had no effect on either glucagon or glucose responses during mixed-meal testing in type 1 diabetes — a striking failure for a drug that effectively suppresses glucagon in type 2 diabetes.
Why it matters
Post-meal blood sugar spikes are one of the biggest challenges in type 1 diabetes management, and excessive glucagon release is a key driver. This head-to-head comparison reveals that pramlintide — a synthetic version of the pancreatic peptide amylin — can suppress this glucagon surge, while liraglutide cannot. This matters because it clarifies which peptide drug actually addresses a fundamental problem in T1D management.
The numbers in context
Pramlintide group: n=8, age 20±3, HbA1c 6.9% · Liraglutide group: n=10, age 22±3, HbA1c 7.6% · Glucagon AUC: -63% with pramlintide (p<0.001) · Glucose AUC: -79% with pramlintide (p<0.01) · Liraglutide: no significant change
How the study worked
Two parallel clinical studies in young adults with type 1 diabetes. Participants underwent mixed-meal tolerance tests (MMTTs) without premeal bolus insulin before and after 3–4 weeks of treatment with either pramlintide (n=8) or liraglutide (n=10). Plasma glucagon and glucose responses were measured over 120 minutes post-meal.
Who was studied
18 young adults with type 1 diabetes (8 pramlintide, 10 liraglutide)
What this study cannot tell us
Very small sample sizes (8 and 10 patients). The two groups were not randomized against each other — they were parallel studies, making direct comparison less rigorous. No placebo control within either group. Short treatment duration (3–4 weeks). The MMTT was performed without premeal insulin, which doesn't reflect real-world diabetes management.
How to read the evidence
This is a small clinical study (18 total patients) with parallel groups but no placebo control or randomization between treatments. The within-group comparisons (before vs after treatment) show strong statistical significance, but the small sample sizes and study design limit generalizability.
When this study was published
Published in 2018, this study addresses an ongoing clinical question about adjunctive therapies for type 1 diabetes. Interest in amylin-based approaches has grown since, with newer formulations in development.
The bigger picture
While GLP-1 drugs have revolutionized type 2 diabetes treatment, their role in type 1 diabetes remains uncertain. This study illustrates that amylin — the 'other' pancreatic peptide lost in T1D alongside insulin — may be more physiologically relevant. Pramlintide (Symlin) is the only FDA-approved amylin analog, and it's underutilized. These results support growing interest in dual-hormone approaches (insulin + amylin) for T1D management.
Questions still open
- Would combining pramlintide with a closed-loop insulin pump system further improve post-meal glucose control in type 1 diabetes?
- Why does liraglutide suppress glucagon effectively in type 2 diabetes but not in type 1 — is it because T1D patients lack residual beta cell function?
- Could newer amylin analogs with better pharmacokinetics replace pramlintide and gain wider clinical adoption?
Common questions
What is pramlintide and how is it different from insulin?
Why doesn't liraglutide work for glucagon suppression in type 1 diabetes?
Read the original research
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
The Journal of clinical endocrinology and metabolism, 103(3), 1088-1094
Citation
Galderisi, Alfonso; Sherr, Jennifer; VanName, Michelle; Carria, Lori; Zgorski, Melinda; Tichy, Eileen; Weyman, Kate; Cengiz, Eda; Weinzimer, Stuart; Tamborlane, William. (2018). Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.. The Journal of clinical endocrinology and metabolism, 103(3), 1088-1094. https://doi.org/10.1210/jc.2017-02265